Arrowhead rises as analyst upgrade spotlights plozasiran Phase 3 catalysts
Arrowhead Pharmaceuticals (ARWR) is rising after an analyst upgrade revived bullish sentiment around plozasiran’s Phase 3 outlook in severe hypertriglyceridemia. The move extends a recent bid tied to expectations for mid-2026 topline data and potential regulatory filings thereafter.
1) What’s driving ARWR today
Arrowhead Pharmaceuticals shares moved higher as trading digested a fresh bullish analyst call that upgraded the stock and lifted the price target, pointing to improving confidence in plozasiran’s Phase 3 setup in severe hypertriglyceridemia (SHTG). (sahmcapital.com)
2) Why plozasiran is the focus
Plozasiran is Arrowhead’s lead cardiometabolic program, and investors are positioning ahead of multiple Phase 3 readouts expected in 2026. The company has said the primary portions of key Phase 3 studies are expected to finish in mid-2026, with topline data expected shortly afterward, setting up potential follow-on regulatory steps. (ir.arrowheadpharma.com)
3) What to watch next
Near-term sentiment for ARWR is likely to remain headline-sensitive around clinical and regulatory milestones for plozasiran, including timelines for SHTG readouts and any signals on filing strategy. Separately, Arrowhead has flagged additional pipeline catalysts later in 2026, including initial human data from its ARO-MAPT program in the second half of 2026. (finance.yahoo.com)